How Can MPN Clinical Trials Be Diversified?
How Can MPN Clinical Trials Be Diversified? from Patient Empowerment Network on Vimeo.
How can myeloproliferative neoplasm (MPN) clinical trials participants become more diversified? Expert Dr. Idoroenyi Amanam from City of Hope explains how MPN clinicians, institutions, pharma companies, and others can help expand the participant pool for all population groups.
Related Resources:
What Does the Future of Myeloproliferative Neoplasm Care Look Like? |
Understanding MPN Treatment Goals and Shared Decision-Making |
|
Transcript:
Lisa Hatfield:
Dr. Amanam, how can we better encourage more diverse participation in MPN or any cancer clinical trials?
Dr. Indoroenyi Amanam:
This is a great question. I think that going back to the idea that we want to practice the best science, we want to be able to publish the best data. The responsibility is on the clinicians, the scientists, the clinical trialists, the drug companies, the institutions to really be able to structure clinical trials that are relevant to our real world experience. And so how can we better encourage that? I think from a government perspective, potentially incentivizing drug companies and institutions and the other major players that really are involved in pushing this field forward to practice better science. I think we put so much of responsibility on the clinical trial participants, and we’ve spent many years really analyzing or thinking about the reasons why the clinical trial participants are not or the lack of clinical trial participants is from specific groups.
But I think we have to put that look at us, the scientists, the physicians, the institutions, the companies. What are we not doing right here? And I think we have to put a lot of energy there. And once we’re clear that being able to have a diverse participant pool will give us the best results and therefore will lead to your drug being approved. I think we will have more participants from all groups.
Share Your Feedback
Create your own user feedback survey
